期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
1
作者 Manreet Randhawa Gregory Gaughran +4 位作者 Christine Archer Paul Pavli adrienne morey Sayed Ali Desmond Yip 《World Journal of Clinical Oncology》 CAS 2019年第10期350-357,共8页
BACKGROUND Dual checkpoint inhibition improves response rates in treatment naive patients with metastatic melanoma compared to monotherapy.However,it confers a higher rate of toxicity,including immune-related colitis.... BACKGROUND Dual checkpoint inhibition improves response rates in treatment naive patients with metastatic melanoma compared to monotherapy.However,it confers a higher rate of toxicity,including immune-related colitis.Steroids may not resolve symptoms in all cases.The use of vedolizumab,a humanized monoclonal antibody againstα4β7 integrin has proven effective in cases refractory to standard treatment.CASE SUMMARY We report the case of a 27-year-old female with Stage IVd metastatic melanoma treated with ipilimumab and nivolumab.She developed severe colitis refractory to methylprednisolone,infliximab and mycophenolate mofetil but responded to vedolizumab.CONCLUSION This case report supports vedolizumab use in severe immune related colitis refractory to standard immunosuppression. 展开更多
关键词 IPILIMUMAB Nivolumab Metastatic melanoma STEROID-REFRACTORY COLITIS Infliximab-refractory COLITIS Vedolizumab Case report
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部